In clinical and experimental studies, elevated levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), are associated with endothelial dysfunction and atherosclerotic burden [3–8]. This evidence concerns the gene NOS1 and endothelial dysfunction.